The stock's high price tag could be a problem for investors looking for a big return. Summit Therapeutics (NASDAQ: SMMT) has ...

Biotech investors are preparing for what may be the most important clinical trial readout for them this summer.

Summit Therapeutics Inc. (NASDAQ: SMMT) ("Summit," "we," or the "Company") today announced the grant of inducement awards of ...

Summit Therapeutics Inc. is a biopharmaceutical oncology company focused on the discovery, development, and commercialization of patient-, physician-, caregiver- and societal-friendly medicinal ...

MIAMI, May 16, 2025--(BUSINESS WIRE)--Summit Therapeutics Inc. (NASDAQ: SMMT) ("Summit," "we," or the "Company") today announced the grant of inducement awards of options to purchase a collective ...

Summit Therapeutics (NASDAQ: SMMT) has more than just a potential blockbuster cancer drug in its portfolio. Ivonescimab could be one of the best drugs to ever hit the market. This has investors ...

The consistent outperformance in multiple forms of administration against multiple existing standards of care is certainly very bullish for Summit, whose stock is nearly all the way back to an ...

Q1 2025 Earnings Call Transcript May 19, 2025 Operator: Greetings, and welcome to the Brainstorm Cell Therapeutics First ...

The bullish case for Summit Therapeutics, and the reason the stock has been soaring in the past year, is that it's potentially sitting on a drug that could generate tens of billions in revenue.

Discover Summit Therapeutics' Q1 2025 milestones, including ivonescimab progress, the global HARMONi trial, and strategic oncology collaborations.